Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Deferred Revenue: 2015-2024

Historic Current Deferred Revenue for vTv Therapeutics (VTVT) over the last 9 years, with Dec 2024 value amounting to $18.7 million.

  • vTv Therapeutics' Current Deferred Revenue fell 0.09% to $18.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.7 million, marking a year-over-year decrease of 0.09%. This contributed to the annual value of $18.7 million for FY2024, which is 0.09% down from last year.
  • According to the latest figures from Q4 2024, vTv Therapeutics' Current Deferred Revenue is $18.7 million, which was up 109,717.65% from $17,000 recorded in Q3 2024.
  • Over the past 5 years, vTv Therapeutics' Current Deferred Revenue peaked at $18.7 million during Q2 2022, and registered a low of $17,000 during Q4 2022.
  • Moreover, its 3-year median value for Current Deferred Revenue was $18.7 million (2023), whereas its average is $10.9 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 109,817.65% in 2023, then crashed by 99.91% in 2024.
  • Over the past 5 years, vTv Therapeutics' Current Deferred Revenue (Quarterly) stood at $31,000 in 2020, then rose by 12.90% to $35,000 in 2021, then crashed by 51.43% to $17,000 in 2022, then spiked by 109,817.65% to $18.7 million in 2023, then declined by 0.09% to $18.7 million in 2024.
  • Its Current Deferred Revenue stands at $18.7 million for Q4 2024, versus $17,000 for Q3 2024 and $17,000 for Q2 2024.